FDA gives nod for Apellis’ injection to treat geographic atrophy
Apellis Pharmaceuticals, a US-based biopharmaceutical company, has got FDA approval for a drug to treat geographic atrophy, the company announced.
Drugs
Medical
Pharma
Drugs
Pharma
Glenmark gets 2nd FDA nod for high blood sugar drug
Glenmark Pharmaceuticals, a US-based company, has received a tentative second FDA approval for its oral drug to treat high blood pressure.
Drugs
Medical
Pharma
GE Healthcare recalls 688 medical systems, FDA says ‘most serious’
GE Healthcare has pulled out 688 medical systems that evaluate diseases, trauma, abnormalities and disorders, a move which USFDA termed a most severe.
Drugs
Pharma
Lupin gets FDA nod for injection to lessen saliva, stomach acid
Lupin Limited, an Indian maker of branded, generic formulations, biotechnology products, and active pharmaceutical ingredients, has got USFDA approval for its ANDA injection,.
Drugs
Pharma
Global Pharma recalls eye drops after FDA contamination warning
India-based Global Pharma Healthcare voluntarily recalled all lots of its artificial tears lubricant eye drops after the USFDA reported possible contamination.
Drugs
Medical
Pharma
GSK Plc gets FDA nod to make oral drug for anaemic CKD patients
GSK Plc., a British global pharmaceutical company, announced the FDA had approved an oral drug to treat anaemia arising from chronic kidney disease.
Drugs
Medical
Pharma
Eli Lilly gets FDA nod for blood cancer drug
Eli Lilly announced that it had received US FDA approval for a tablet to treat a rare form of blood cancer.
Drugs
Medical
Pharma
US health regulator says heart devices recall “most serious”
A recall of Swedish makers' of heart devices has been classified by the FDA as "most serious" since they could lead to severe.
Drugs
Pharma
Eli Lilly plans $450 million extra to expand Research Triangle
Eli Lilly will invest an additional $450 million to expand its manufacturing capacity at Research Triangle Park facility in North Carolina.
Drugs
Pharma
USFDA grants ‘tentative approval’ to Zydus’ mental health drug
The USFDA has granted Zydus Lifesciences Limited ‘tentative approval’ to market Levomilnacipran extended-release capsules in 20 mg, 40 mg, 80 mg, and 120.